Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Brazilian Clinical Research Institute
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06396858CT.gov Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke | — | Not Yet Recruiting | — | — | — |
NCT07468448CT.gov Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS) | — | Not Yet Recruiting | — | — | — |
NCT05700266CT.gov Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis | — | Unknown | — | — | — |
NCT03684564CT.gov RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome | — | Completed | — | — | — |
NCT06144866CT.gov Evaluataion of NOAC Levels in Acute Stroke | — | Unknown | — | — | — |
NCT04142125CT.gov Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease | — | Completed | — | — | — |
NCT03568916CT.gov Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs) | — | Completed | — | — | — |
NCT02042534CT.gov Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation | — | Completed | — | — | — |
NCT01923818CT.gov Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ischemic Stroke
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rivaroxaban (this asset) | Brazilian Clinical Research Institute | Approved | BB · 68 |
| Ticagrelor | Sichuan Provincial People's Hospital | P4 | BBB |
| Cilostazol | Stanford University | P4 | BBB |
| Compound Edaravone | Nanfang Hospital, Southern Medical University | P4 | BBB |
| 3-N-BUTYLPHTHALIDE | Nanfang Hospital, Southern Medical University | P4 | BBB |
| Tenecteplase | Hackensack Meridian Health | P4 | BBB |
| Argatroban | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Aspirin | Nanfang Hospital, Southern Medical University | P4 | BB |
| Prednisolone | University of California, San Francisco | P4 | BB |
+42 more in the Ischemic Stroke cohort
Other indications for Rivaroxaban
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Atrial Fibrillation | — | P4 | BBB · 79 |
| Hemorrhagic Disease | — | P4 | BBB · 76 |
| Thrombotic Disease | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rivaroxaban in Ischemic Stroke. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rivaroxaban-ischemic-stroke
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →